Merck to Acquire Tilos TherapeuticsAcquisitions, Anti-LAP Antibodies, Autoimmune Diseases, Biopharmaceutical, Business, Cancer, Cytokines, Fibrosis, Fibrotic Diseases, Latency-Associated Peptide (LAP), Oncology, Strategy, Transforming Growth Factor-beta (TGFb)Merck agreed to acquire Tilos, a privately held biopharma company developing therapeutics targeting the latent TGFβ complex for the treatment of cancer, fibrosis and autoimmune diseases. Read more June 10, 2019/by Business Wire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Business Wire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Business Wire2019-06-10 06:45:392019-06-10 13:28:37Merck to Acquire Tilos Therapeutics